Market revenue in 2023 | USD 515.7 million |
Market revenue in 2030 | USD 710.5 million |
Growth rate | 4.7% (CAGR from 2023 to 2030) |
Largest segment | Frozen nondonor |
Fastest growing segment | Fresh Donor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Fresh Nondonor, Frozen Nondonor, Fresh Donor, Frozen Donor |
Key market players worldwide | Bayer AG, Cook Medical, Merck KGaA, Ferring, FUJIFILM Holdings Corp, Genea Biomedx, Merck & Co Inc, The Cooper Companies Inc, Thermo Fisher Scientific Inc, Vitrolife AB ADR, Boston Scientific Corp, Nova IVF, Fortis Healthcare, RMA Network, TFP Fertility Group, US Fertility |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to in vitro fertilization market will help companies and investors design strategic landscapes.
Frozen nondonor was the largest segment with a revenue share of 48.44% in 2023. Horizon Databook has segmented the Belgium in vitro fertilization market based on fresh nondonor, frozen nondonor, fresh donor, frozen donor covering the revenue growth of each sub-segment from 2018 to 2030.
In Belgium, a higher number of women opt for IVF procedures compared to other European countries owing to favorable reimbursement policies, wherein the national health plan and private insurance offer complete reimbursement coverage for up to six ART cycles.
Moreover, women from countries such as Netherlands and France travel to Belgium for ART procedures due to factors such as quality of reproductive care, easy access to IVF treatment, beneficial regulatory schemes, and failure of previous procedures in the home country.
The legal limit of embryo transfer in a single cycle is one in patients under 36 years. The growth of IVF market in Belgium can be attributed to the transition of IVF as the dominant method of ART procedure, supportive reimbursement scenario, affordability, and absence of cultural barriers in assisted childbirth in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Belgium in vitro fertilization market , including forecasts for subscribers. This country databook contains high-level insights into Belgium in vitro fertilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account